Another milestone for Roboderm® technology in the US market
We are thrilled to announce that the US Food and Drug Administration (FDA) has cleared the new icoone range laser devices. This further clearance for our Roboderm technology marks yet another milestone on icoone’s path towards commercialization in the US market.
icoone’s latest generation of microstimulations, with +25% increase in the active surface of stimulation, introduces an evolved approach in reducing the appearance of cellulite, improving local blood circulation and relieving muscle aches and spasms. Microstimulations in combination with 650 nm wavelength LED and 950 nm wavelength laser help to achieve faster results and to make them more long-lasting.
A number of other new features, such us additional handpieces, a more intuitive user interface and new programmes, will now provide physicians and aesthetic operators a non-invasive cutting-edge technology for more tailored treatments, uniquely designed for a comfortable, relaxing patient experience.
Luca Gualdrini, i-Tech’s General Manager says “We’re proud to have achieved this new clearance. It marks the next step in our worldwide distribution plans and we look forward to introducing it to our clients for them to experience a technology whose main goal is to deliver results.”